......... DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER Corporate Presentation – May 2022 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus compet ...

Kura Oncology, Inc. (NASDAQ:KURA) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Troy Wilson – Chairman and Chief Executive Officer Tom Doyle – Senior Vice President, Finance and Accounting Pete De Spain – Senior Vice President, Investor Relations and Corporate Communications Conference Call Participants Jonathan Chang – SVB Securities Peter Lawson – Barclays Corporate & Investment Bank Jonathan Ofertiago – Credit Suisse Roger Song – Jefferies Reni Benjamin – JMP Securities Eva ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 12730 Hi ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER ......... Corporate Presentation – February 2022 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for ziftomenib, tipifarnib and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus c ...

Kura Oncology, Inc. (NASDAQ:KURA) Q4 2021 Earnings Conference Call February 24, 2022 4:30 PM ET Company Participants Troy Wilson – Chairman, Chief Executive Officer & President Tom Doyle – Senior Vice President of Finance and Accounting Pete De Spain – Vice President, Investor Relations & Corporate Communications Conference Call Participants Jonathan Chang – SVB Leerink Peter Lawson – Barclays Bank Tiago Fauth – Crédit Suisse Ren Benjamin – JMP Securities Roger Song – Jefferies Phil Nadeau – Cowen and Compa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37620 KURA ONCOLOGY, INC. (Exact name of Registrant as specified in its Charter) Delaware 61-1547851 12730 High Bluff Drive, Suite 40 ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2021 Earnings Conference Call November 4, 2021 4:30 PM ET Company Participants Pete De Spain - VP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Marc Grasso - CFO & Chief Business Officer Stephen Dale - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Tiago Fauth - Crédit Suisse Peter Lawson - Barclays Bank Ren Benjamin - JMP Securities Joe Pantginis - H.C. Wainwright Eva Previtera - Cowen Operator Good day, and welc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ________ To ________ Commission file number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...

DEVELOPING PRECISION MEDICINES FOR THE TREATMENT OF CANCER 0 0 Corporate Presentation – September 2021 Forward-Looking Statements This presentation contains forward-looking statements. Such statements include, but are not limited to, statements regarding our research, preclinical and clinical development activities, plans and projected timelines for tipifarnib, KO-539 and KO-2806, plans regarding regulatory filings, our expectations regarding the relative benefits of our product candidates versus competitiv ...

Kura Oncology, Inc. (NASDAQ:KURA) Q2 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Pete De Spain - VP, IR & Corporate Communications Troy Wilson - Chairman, CEO & President Marc Grasso - CFO & Chief Business Officer Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Barclays Bank Tiago Fauth - Crédit Suisse Reni Benjamin - JMP Securities Philip Nadeau - Cowen and Company Operator Good day, and thank you for standing by, and welcome to the Second Quarter 2 ...